Hillevax Inc
HLVX2.052USD
+0.012+0.58%
Market hours （ET）Quotes delayed by 15 min
102.80MMarket Cap
LossP/E TTM
More Details of Hillevax Inc Company
HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The Company's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-216 includes six common norovirus genotypes, GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.
Company Info
Ticker SymbolHLVX
Company nameHillevax Inc
IPO dateApr 29, 2022
CEODr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Number of employees14
Security typeOrdinary Share
Fiscal year-endApr 29
Address321 Harrison Ave, Suite 500
CityBOSTON
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02118
Phone16172135054
Websitehttps://www.hillevax.com/
Ticker SymbolHLVX
IPO dateApr 29, 2022
CEODr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
876.86K
+11.51%
Mr. Jaime Sepulveda, M.D.
Mr. Jaime Sepulveda, M.D.
Independent Director
Independent Director
59.22K
+40.93%
Ms. Jeryl Hilleman
Ms. Jeryl Hilleman
Independent Director
Independent Director
59.22K
+40.93%
Mr. Shane Maltbie, CPA
Mr. Shane Maltbie, CPA
Chief Financial Officer
Chief Financial Officer
38.30K
-52.06%
Dr. Gary Dubin, M.D.
Dr. Gary Dubin, M.D.
Independent Director
Independent Director
17.20K
--
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Lead Independent Director
Lead Independent Director
17.20K
--
Dr. Nanette Cocero, Ph.D.
Dr. Nanette Cocero, Ph.D.
Independent Director
Independent Director
17.20K
--
Dr. Shelley Chu, M.D., Ph.D.
Dr. Shelley Chu, M.D., Ph.D.
Independent Director
Independent Director
17.20K
--
Dr. Aditya Kohli, Ph.D.
Dr. Aditya Kohli, Ph.D.
Director
Director
--
--
Dr. Julie Louise Gerberding, M.D.
Dr. Julie Louise Gerberding, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
876.86K
+11.51%
Mr. Jaime Sepulveda, M.D.
Mr. Jaime Sepulveda, M.D.
Independent Director
Independent Director
59.22K
+40.93%
Ms. Jeryl Hilleman
Ms. Jeryl Hilleman
Independent Director
Independent Director
59.22K
+40.93%
Mr. Shane Maltbie, CPA
Mr. Shane Maltbie, CPA
Chief Financial Officer
Chief Financial Officer
38.30K
-52.06%
Dr. Gary Dubin, M.D.
Dr. Gary Dubin, M.D.
Independent Director
Independent Director
17.20K
--
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Lead Independent Director
Lead Independent Director
17.20K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Jul 29
Updated: Tue, Jul 29
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Frazier Life Sciences Management, L.P.
21.17%
Takeda Pharmaceutical Co Ltd
13.41%
Tang Capital Management, LLC
9.81%
EcoR1 Capital, LLC
5.77%
Lightspeed Venture Partners
4.59%
Other
45.24%
Shareholders
Shareholders
Proportion
Frazier Life Sciences Management, L.P.
21.17%
Takeda Pharmaceutical Co Ltd
13.41%
Tang Capital Management, LLC
9.81%
EcoR1 Capital, LLC
5.77%
Lightspeed Venture Partners
4.59%
Other
45.24%
Shareholder Types
Shareholders
Proportion
Private Equity
22.82%
Hedge Fund
16.80%
Investment Advisor/Hedge Fund
15.22%
Corporation
13.41%
Investment Advisor
11.56%
Venture Capital
9.11%
Individual Investor
3.71%
Research Firm
1.02%
Bank and Trust
0.08%
Other
6.27%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
224
44.13M
88.00%
-14.24M
2025Q1
229
46.31M
92.39%
-14.77M
2024Q4
226
47.12M
94.62%
-13.67M
2024Q3
218
46.00M
92.53%
-13.52M
2024Q2
202
49.77M
100.23%
-2.02M
2024Q1
182
48.47M
97.79%
-558.66K
2023Q4
166
46.57M
96.99%
+4.81M
2023Q3
161
39.77M
86.30%
+8.72M
2023Q2
146
30.99M
80.52%
+1.24M
2023Q1
140
32.25M
85.25%
+3.76M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Frazier Life Sciences Management, L.P.
10.62M
21.17%
--
--
Mar 31, 2025
Takeda Pharmaceutical Co Ltd
6.72M
13.41%
--
--
Mar 31, 2025
Tang Capital Management, LLC
4.92M
9.81%
--
--
May 02, 2025
Lightspeed Venture Partners
2.30M
4.59%
-37.51K
-1.60%
Mar 31, 2025
Franklin Advisers, Inc.
1.95M
3.9%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.92M
3.82%
-70.63K
-3.56%
Mar 31, 2025
Deerfield Management Company, L.P.
1.88M
3.75%
--
--
Mar 31, 2025
Abingworth Management Limited
1.84M
3.67%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.59M
3.16%
-20.50K
-1.28%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
Fidelity MSCI Health Care Index ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Global X Russell 2000 ETF
0%
Avantis Responsible US Equity ETF
0%
iShares Russell 2000 Value ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
View more
iShares Micro-Cap ETF
Proportion0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0%
Fidelity MSCI Health Care Index ETF
Proportion0%
Fidelity Nasdaq Composite Index ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Avantis Responsible US Equity ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
ProShares Ultra Nasdaq Biotechnology
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
